The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 501–600 of 1,003
Nutrition and Anabolic Pharmacotherapies in the Care of Burn Patients
Abdullahi, A., & Jeschke, M. G. (2014) · Nutrition in Clinical Practice · doi:10.1177/0884533614533129 · Cited by 62
Beta cell connectivity in pancreatic islets: a type 2 diabetes target?
Rutter, G. A., & Hodson, D. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1755-4 · Cited by 62
Enteroendocrine Dynamics – New Tools Reveal Hormonal Plasticity in the Gut
Beumer, J., Gehart, H., & Clevers, H. C. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa018 · Cited by 68
A synthetic glucagon-like peptide-1 analog with improved plasma stability
Ritzel, U., Leonhardt, U., Ottleben, M., Rühmann, A., Eckart, K., Spiess, J., & Ramadori, G. P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590093 · Cited by 61
A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling
Ehses, J. A., Lee, S. S. T., Pederson, R. A., & McIntosh, C. H. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103023200 · Cited by 61
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
Self-citationFarhadipour, M., & Depoortere, I. (2021) · Nutrients · doi:10.3390/nu13061839 · Cited by 65
Hamamoto, S., Kanda, Y., Shimoda, M., Tatsumi, F., Kohara, K., Tawaramoto, K., Hashiramoto, M., & Kaku, K. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12005 · Cited by 61
Jean, M., Alameh, M., Buschmann, M. D., & Merzouki, A. (2011) · Gene Therapy · doi:10.1038/gt.2011.25 · Cited by 61
Naylor, J., Suckow, A. T., Seth, A., Baker, D. J., Sermadiras, I., Ravn, P., Howes, R., Li, J., Snaith, M. R., Coghlan, M. P., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160476 · Cited by 60
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 59
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 63
Ren, W., Chen, J., Wang, W., Li, Q., Yin, X., Zhuang, G., Zhou, H., & Zeng, W. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.012 · Cited by 62
Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.009 · Cited by 62
Wang, A., Dorso, C. R., Kopcho, L. M., Locke, G. A., Langish, R. A., Harstad, E. B., Shipkova, P. A., Marcinkeviciene, J. A., Hamann, L. G., & Kirby, M. (2012) · BMC Pharmacology · doi:10.1186/1471-2210-12-2 · Cited by 59
Seimon, R. V., Brennan, I. M., Russo, A., Little, T. J., Jones, K. L., Standfield, S., Wishart, J. M., Horowitz, M., & Feinle‐Bisset, C. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00533.2012 · Cited by 59
Irwin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 61
Watson, L. E., Phillips, L. K., Wu, T., Bound, M. J., Checklin, H. L., Grivell, J., Jones, K. L., Clifton, P. M., Horowitz, M., & Rayner, C. K. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13604 · Cited by 59
Amino acid transporters in the regulation of insulin secretion and signalling
Javed, K., & Fairweather, S. J. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180250 · Cited by 64
Irwin, N., Green, B. D., Mooney, M. H., Greer, B., Harriott, P., Bailey, C. J., Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086082 · Cited by 59
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Wu, T., Bound, M. J., Zhao, B. R., Standfield, S., Bellon, M., Jones, K. L., Horowitz, M., & Rayner, C. K. (2013) · Diabetes Care · doi:10.2337/dc12-2294 · Cited by 58
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 60
Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide
Meier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 59
Self-citationDipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes
Augustyns, K., der Veken, P. V., Senten, K., & Haemers, A. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.4.499 · Cited by 58
Green, B., Mooney, M., Gault, V., Irwin, N., Bailey, C., Harriott, P., Greer, B., O'Harte, F., & Flatt, P. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800379 · Cited by 57
Mohammad, S., Ramos, L. S., Buck, J., Levin, L. R., Rubino, F., & McGraw, T. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.289009 · Cited by 59
Coffee consumption and cardiometabolic health: a comprehensive review of the evidence
Ungvari, Z. I., & Kunutsor, S. K. (2024) · GeroScience · doi:10.1007/s11357-024-01262-5 · Cited by 69
Dietary Effects on Incretin Hormone Secretion
Wu, T., Rayner, C. K., Jones, K. L., & Horowitz, M. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00003-5 · Cited by 58
Pratley, R. E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802694713 · Cited by 57
Herzberg-Schäfer, S. A., Heni, M., Stefan, N., Häring, H., & Fritsche, A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 59
Gelidium elegans Extract Ameliorates Type 2 Diabetes via Regulation of MAPK and PI3K/Akt Signaling
Choi, J., Kim, K., Koh, E., & Lee, B.-Y. (2018) · Nutrients · doi:10.3390/nu10010051 · Cited by 58
Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Self-citationClinical evidence and mechanistic basis for vildagliptin's action when added to metformin
Åhrén, B., Foley, J. E., & Bosi, E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01321.x · Cited by 56
Alssema, M., Rijkelijkhuizen, J. M., Holst, J. J., Teerlink, T., Scheffer, P. G., Eekhoff, E. M. W., Gastaldelli, A., Mari, A., Hart, L. M. ‘., Nijpels, G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0487 · Cited by 59
Self-citationDiabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Skow, M., Bergmann, N. C., & Knop, F. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12685 · Cited by 57
Mulvihill, E. E. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.023 · Cited by 57
Pancreatic and Extrapancreatic Effects of Gastric Inhibitory Polypeptide
Yamada, Y., Miyawaki, K., Tsukiyama, K., Harada, N., Yamada, C., & Seino, Y. (2006) · Diabetes · doi:10.2337/db06-s011 · Cited by 55
Tseng, C., Boylan, M. O., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e661 · Cited by 56
The ageing entero-insular axis
Ranganath, L. R., Sedgwick, I., Morgan, L. D., Wright, J., & Marks, V. (1998) · Diabetologia · doi:10.1007/s001250051070 · Cited by 56
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 59
Gabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & ROSENKILDE, M. M. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55
Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
Nagakura, T., Yasuda, N., Yamazaki, K., Ikuta, H., & Tanaka, I. (2003) · Metabolism · doi:10.1053/meta.2003.50014 · Cited by 55
Fujii, Y., Osaki, N., Hase, T., & Shimotoyodome, A. (2015) · Journal of Nutritional Science · doi:10.1017/jns.2014.71 · Cited by 55
Lu, W. J., Yang, Q., Sun, W. Y., Woods, S. C., D’Alessio, D. A., & Tso, P. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00146.2007 · Cited by 55
Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Peterson, G. E., & Pollom, R. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02498.x · Cited by 55
GPR119: “Double-Dipping” for Better Glycemic Control
Lauffer, L., Iakoubov, R., & Brubaker, P. L. (2008) · Endocrinology · doi:10.1210/en.2008-0182 · Cited by 55
Theodorakis, M. J., Carlson, O. D., Muller, D. C., & Egan, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1692 · Cited by 56
GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_3 · Cited by 56
Kang, Z., Deng, Y., Zhou, Y., Fan, R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2012) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 55
Al‐Sabah, S., Al-Fulaij, M. A., Shaaban, G., Ahmed, H. A., Mann, R. J., Donnelly, D., Bünemann, M., & Krasel, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106890 · Cited by 54
Ahrén, B., Larsson, H. E., & Holst, J. J. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370127 · Cited by 54
Self-citationHolst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 72
Self-citationIrwin, N., Gault, V. A., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513381 · Cited by 55
Does long-term coffee intake reduce type 2 diabetes mellitus risk?
Pimentel, G. D., Zemdegs, J. C. S., Theodoro, J. A., & Mota, J. F. (2009) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-1-6 · Cited by 53
Nauck, M. A., Kind, J., Köthe, L., Holst, J. J., Deacon, C. F., Broschag, M., He, Y. L., Kjems, L., & Foley, J. E. (2016) · Diabetes · doi:10.2337/db16-0107 · Cited by 52
Self-citationPratley, R. E. (2008) · PubMed Central · Cited by 52
Neumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 55
Aaboe, K., Knop, F. K., Vilsbøll, T., Vølund, A., Simonsen, U., Deacon, C. F., Madsbad, S., Holst, J. J., & Krarup, T. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1731 · Cited by 52
Self-citationWu, T., Ma, J., Bound, M. J., Checklin, H. L., Deacon, C. F., Jones, K. L., Horowitz, M., & Rayner, C. K. (2014) · Diabetes · doi:10.2337/db13-1627 · Cited by 51
Zhang, X., Young, R. L., Bound, M. J., Hu, S., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2019) · Diabetes Care · doi:10.2337/dc18-2156 · Cited by 52
GIP analogues and the treatment of obesity-diabetes
Bailey, C. J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170202 · Cited by 54
Incretins, diabetes, and bariatric surgery: a review
Fetner, R., McGinty, J., Russell, C. D., Pi-Sunyer, X., & Laferrère, B. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.09.001 · Cited by 52
GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity
Fyfe, M. C. T., McCormack, J. G., Overton, H. A., Procter, M. J., & Reynet, C. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.4.403 · Cited by 52
Iwasaki, M., Minami, K., Shibasaki, T., Miki, T., Miyazaki, J., & Seino, S. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00026.x · Cited by 51
Incretin Hormone Secretion Over the Day
Åhrén, B., Carr, R. D., & Deacon, C. F. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00007-2 · Cited by 52
Vollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 52
Self-citationIncretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
Knop, F. K., Hansen, K. B., & Knop, F. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s7004 · Cited by 52
Renner, S., Römisch‐Margl, W., Prehn, C. P., Krebs, S., Adamski, J., Göke, B., Blum, H., Suhre, K., Roscher, A. A., & Wolf, E. (2012) · Diabetes · doi:10.2337/db11-1133 · Cited by 51
Deshpande, M. C., Venkateswarlu, V., Babu, R. K., & Trivedi, R. K. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.024 · Cited by 51
Glucagon-like Peptide-1 (GLP-1) and the Control of Glucose Metabolism in Mammals and Teleost Fish
Mojsov, S. (2000) · American Zoologist · doi:10.1668/0003-1569(2000)040[0246:glpgat]2.0.co;2 · Cited by 56
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Gallwitz, B. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s23166 · Cited by 50
Coffee consumption, serum γ-glutamyltransferase and risk of type II diabetes
Bidel, S., Silventoinen, K., Hu, G., Lee, D., Kaprio, J. A., & Tuomilehto, J. O. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602712 · Cited by 55
O'Harte, F. P. M., Mooney, M., Kelly, C. M., & Flatt, P. R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650639 · Cited by 50
The incretin hormones: from scientific discovery to practical therapeutics
Mudaliar, S. R. D., & Henry, R. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2561-x · Cited by 50
Borner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 48
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Piccini, S., Favacchio, G., Panico, C., Morenghi, E., Folli, F. B., Mazziotti, G., Lania, A. G., & Mirani, M. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01800-z · Cited by 53
Incretin-based therapies: mimetics versus protease inhibitors
Brubaker, P. L. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.06.005 · Cited by 49
Martin, C. M., Gault, V. A., McClean, S., Flatt, P. R., & Irwin, N. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.04.015 · Cited by 49
Westberg-Rasmussen, S., Starup‐Linde, J., Hermansen, K., Holst, J. J., Hartmann, B., Vestergaard, P., & Gregersen, S. (2017) · Bone · doi:10.1016/j.bone.2017.01.027 · Cited by 50
Self-citationRehman, K., Ali, M. B., & Akash, M. S. H. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108670 · Cited by 49
Milk in the prevention and management of type 2 diabetes: The potential role of milk proteins
Hidayat, K., Du, X., & Shi, B. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3187 · Cited by 52
Henquin, J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101212 · Cited by 48
New treatments in type 2 diabetes: a focus on the incretin‐based therapies
Barnett, A. H. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 50
Jia, X., Brown, J. C., Ma, P., Pederson, R. A., & McIntosh, C. H. S. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.4.e645 · Cited by 49
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
Aaboe, K., Akram, S., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12395 · Cited by 49
Self-citationHansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2594 · Cited by 48
Self-citationGLP-1 gene delivery for the treatment of type 2 diabetes
Oh, S., Lee, M., Ko, K. S., Choi, S.-A., & Kim, S. W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00036-4 · Cited by 48
Mauvais‐Jarvis, F., & Kahn, C. R. (2000) · PubMed · Cited by 48
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Lipopeptides development in cosmetics and pharmaceutical applications: A comprehensive review
Pilz, M., Cavelius, P., Qoura, F., Awad, D., & Brück, T. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108210 · Cited by 47
Vildagliptin: A novel oral therapy for type 2 diabetes mellitus
Lauster, C. D., McKaveney, T. P., & Muench, S. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060564 · Cited by 47
Flatt, P. R. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.034 · Cited by 46
Polonsky, K. S., & Burant, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00031-9 · Cited by 53
Li, Y., Glotfelty, E. J., Karlsson, T. E., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 47
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 50
Zangerolamo, L., Carvalho, M. U. W. B. D., & Barbosa, H. C. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146547 · Cited by 56
Maeda, A., Miyagawa, J., Miuchi, M., Nagai, E., Konishi, K., Matsuo, T., Tokuda, M., Kusunoki, Y., Ochi, H., Murai, K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12045 · Cited by 46
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
